Elicio Therapeutics (ELTX) Exchange Rate Effect (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Exchange Rate Effect came in at -$4000.0 in Q2 2026, down 105.41% on a YoY basis from $74000.0 in Q2 2025, and down 180.0% quarter-over-quarter from $5000.0 in Q1 2026.
Powered by 
Analysis
Elicio Therapeutics (ELTX) Exchange Rate Effect (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has reported Exchange Rate Effect for 7 consecutive years, with -$4000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Exchange Rate Effect fell 105.41% year-over-year to -$4000.0; the trailing twelve-month figure through Jun 2026 stood at -$56000.0 (down 133.33% YoY), and the FY2025 full-year result was $48000.0, up 118.18% from the prior year.
- Exchange Rate Effect declined to -$4000.0 in Q2 2026 per ELTX's latest filing, from $5000.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $87000.0 in Q2 2022 and bottomed at -$96000.0 in Q4 2025.
- Historically, Exchange Rate Effect has averaged $5071.4 across 5 years, with a median of $16000.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Exchange Rate Effect sank 2800.0% in 2022, then jumped 1700.0% in 2024.
- Over 5 years, Exchange Rate Effect stood at $87000.0 in 2022, then tumbled by 97.7% to $2000.0 in 2023, then soared by 1250.0% to $27000.0 in 2024, then sank by 455.56% to -$96000.0 in 2025, then soared by 95.83% to -$4000.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$4000.0, $5000.0, and -$96000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -19.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -3.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -300,000.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -2.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -3.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 315,000.00 |
| 10 | Elicio Therapeutics | 40.60 Mn | 17.10 Mn | - | -4,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | -96,000.00 |
| Sep 30, 2025 | 39,000.00 |
| Jun 30, 2025 | 74,000.00 |
| Mar 31, 2025 | 31,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Sep 30, 2024 | 36,000.00 |
| Jun 30, 2024 | -41,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Jun 30, 2023 | -81,000.00 |
| Mar 31, 2023 | 79,000.00 |
| Jun 30, 2022 | 87,000.00 |
| Mar 31, 2022 | -87,000.00 |
| Dec 31, 2021 | 14,000.00 |
| Sep 30, 2021 | -16,000.00 |
| Jun 30, 2021 | 8,000.00 |
| Mar 31, 2021 | -3,000.00 |
| Dec 31, 2020 | -287,000.00 |
| Sep 30, 2020 | -204,000.00 |